TFC Financial Management
ENTA icon

TFC Financial Management’s Enanta Pharmaceuticals ENTA Stock Holding History

TFC Financial Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14 Hold
1
– – ﹤0.01% 1035
2026
Q2 		$15 Hold
1
– – ﹤0.01% 1030
2026
Q1 		$13 Buy
+1
New +$13 ﹤0.01% 990

Other funds holding ENTA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Hillsdale Investment Management
Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

TFC Financial Management's ENTA Position: Q3 2026 in Review

TFC Financial Management held its Enanta Pharmaceuticals (ENTA) position steady in Q3 2026 at 1 share worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

TFC Financial Management first reported a position in ENTA in Q1 2026 and has held it in 3 quarters since. The position peaked at $15 in Q2 2026. 86 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

  • TFC Financial Management held 1 share of Enanta Pharmaceuticals worth $14 as of Q3 2026.
  • TFC Financial Management left its Enanta Pharmaceuticals share count unchanged in Q3 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of TFC Financial Management's portfolio in Q3 2026, its #1035 holding.
  • TFC Financial Management first reported a position in Enanta Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • TFC Financial Management's Enanta Pharmaceuticals position peaked at $15 in Q2 2026.
  • 86 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on TFC Financial Management's 13F filing for Q3 2026, filed 26 Oct 2026.